Assessing Pharmaceutical Innovation in Europe: Therapeutic Advances vs. Unmet Public Health Need
| dc.contributor.author | Costa, Paula | |
| dc.contributor.author | Advinha, Ana Margarida | |
| dc.contributor.author | Oliveira-Martins, Sofia | |
| dc.date.accessioned | 2026-02-13T15:24:19Z | |
| dc.date.available | 2026-02-13T15:24:19Z | |
| dc.date.issued | 2025 | |
| dc.description.abstract | This study presents a comprehensive characterization of novel medicines authorized by the European Commission (EC) between 2014 and 2024, with a focus on evaluating their innovative potential and therapeutic relevance. Beyond descriptive profiling, the study assesses the potential of innovation introduced by these novel drugs and address the alignment between therapeutic indications and unmet medical needs, as determined by the clinical burden of disease, highlighting gaps and opportunities. | por |
| dc.identifier.authoremail | nd | |
| dc.identifier.authoremail | nd | |
| dc.identifier.authoremail | nd | |
| dc.identifier.citation | Costa, P, Advinha AM, Oliveira-Martins S. Assessing Pharmaceutical Innovation in Europe: Therapeutic Advances vs. Unmet Public Health Need. In: Abstracts of the ISPOR Europe 2025. Glasgow, Scotland: Value in Health, 28(S2); 2025. EPH20. | por |
| dc.identifier.doi | https://doi.org/10.1016/j.jval.2025.09.1149 | por |
| dc.identifier.uri | https://www.valueinhealthjournal.com/article/S1098-3015(25)03706-4/abstract?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1098301525037064%3Fshowall%3Dtrue | |
| dc.identifier.uri | http://hdl.handle.net/10174/41157 | |
| dc.language.iso | por | por |
| dc.peerreviewed | no | por |
| dc.rights | openAccess | por |
| dc.title | Assessing Pharmaceutical Innovation in Europe: Therapeutic Advances vs. Unmet Public Health Need | por |
| dc.type | article |